Mind Medicine release topline data from lysergide trial

Mind Medicine announced that Matthias Liechti and Felix Mueller, MindMed collaborators at University Hospital Basel, or UHB, and the University Hospital of Psychiatry, have released topline data from a double-blind, investigator-initiated trial evaluating lysergide in the treatment of MDD. These findings were presented on April 14 in Basel, Switzerland. The topline data demonstrated significant, rapid, durable and beneficial effects of lysergide and its potential to mitigate symptoms of MDD. The high dose lysergide regimen in which patients received 100 microgram at their first dosing day and 200 microgram at their second dosing day resulted in statistically and clinically significant improvements on the primary endpoint, which was the change in clinician-rated Inventory of Depressive Symptomatology, or IDS-C, scores six weeks after the first administration as compared to control. The control group in this study received a lower dose regimen of 25 microgram on both treatment days. Patients in the high dose arm demonstrated a least square mean change from baseline in IDS-C scores of -12.9 points compared to -3.6 points in the lower dose arm. The statistically significant benefit as measured by IDS-C was maintained up to 16 weeks after the first administration compared to placebo. Data from the secondary endpoints were also encouraging. The investigational drug was generally well-tolerated, as indicated by reported adverse events, changes in vital signs and laboratory values.